J1S-MC-JP04 CAMPFIRE (Abemaciclib)

A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing’s Sarcoma



The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolamide) for Ewing's sarcoma that has come back or did not respond to treatment (R/R). This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. 

Abemaciclib is a selective and potent small-molecule cyclin-dependent kinase 4 and cyclin-dependent kinase 6 (CDK4 & 6) inhibitor. Since these kinases are important regulators of the cell cycle in many tumors, inhibition is expected to potentiate the effect of chemotherapy.

Main inclusion criteria

  • Age: ≥ 1 to < 39 years
  • Diagnosis of Relapsed or Refractory Ewing's Sarcoma or Ewing's sarcoma-like tumor
  • Must have one measurable or evaluable lesion
  • Body weight ≥10 kilograms (kg)
  • Karnofsky oder Lansky ≥ 50


Eli Lilly

Diese Webseite verwendet Cookies. Durch die Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Datenschutzinformationen